Single-Donor (Apheresis) vs Random-Donor Platelet Transfusion
Both single-donor apheresis platelets (SDP) and pooled random-donor platelets (RDP) are clinically equivalent in terms of post-transfusion increments, hemostatic benefit, and adverse effects, and can be used interchangeably in routine circumstances 1.
Key Differences Between Products
Preparation Methods
- Single-donor apheresis platelets (SDP): Collected from one donor using automated apheresis technology, yielding approximately 3.0-6.0 × 10¹¹ platelets per unit 2, 3
- Random-donor platelets (RDP): Prepared by pooling 4-6 whole blood-derived platelet concentrates, using either:
- Platelet-rich plasma (PRP) method (common in US)
- Buffy coat (BC) method (common in Europe, Canada, Australia) 1
Clinical Equivalence
The AABB and ASCO guidelines both strongly recommend that these products are interchangeable for routine use 4, 1. Comparative studies demonstrate:
- Similar post-transfusion platelet count increments
- Equivalent hemostatic efficacy
- Comparable adverse event rates when leukoreduced products are used 1
Practical Advantages and Disadvantages
Single-Donor Apheresis Platelets (SDP)
Advantages:
- Markedly reduced donor exposure (1 donor vs 4-6 donors) 5, 6
- Easier logistics for ABO-identical and Rh-compatible matching 5
- Necessary when HLA-matched platelets are required for alloimmunized patients 1
- May reduce alloimmunization risk in chronically transfused patients 6
Disadvantages:
Pooled Random-Donor Platelets (RDP)
Advantages:
- Lower cost per transfusion 1, 5
- More widely available in many settings
- Recent evidence suggests potentially slightly better platelet count increments (4,500/µL higher) in refractory patients 7
Disadvantages:
- Greater donor exposure (4-6 donors per transfusion) 5
- More complex logistics for complete ABO-identical supply 5
- Inevitable wastage of plasma and red cells during preparation 5
When to Choose One Over the Other
Use SDP When:
- HLA-matched platelets are required (alloimmunized patients with documented platelet refractoriness) 1
- Minimizing donor exposure is a priority (e.g., potential transplant candidates)
- ABO-identical products are mandated by institutional policy
Use RDP When:
- Cost considerations are paramount 1
- Routine prophylactic or therapeutic transfusions in non-alloimmunized patients
- SDP products are unavailable
Either Product is Acceptable When:
- Routine prophylactic transfusions for thrombocytopenia 4
- Therapeutic transfusions for bleeding
- All products must be leukoreduced to minimize alloimmunization, CMV transmission, and febrile reactions 1, 8
Dosing Equivalence
The AABB recommends transfusing up to a single apheresis unit or equivalent (typically 4-6 pooled random-donor units) 4. One apheresis unit contains approximately 3.0 × 10¹¹ platelets, roughly equivalent to 4-6 whole blood-derived units 1.
Critical Caveats
- Leukoreduction is essential: Without leukoreduction, the equivalence between products may not hold due to increased alloimmunization and transfusion reactions 1, 8
- ABO compatibility matters: Major and minor ABO-incompatible platelet transfusions may be associated with increased morbidity and mortality 5
- The slight advantage of pooled platelets in refractory patients (4,500/µL increment) is statistically significant but of uncertain clinical significance 7
- German guidelines note non-equivalence exists in some regulatory contexts, requiring physician documentation of product selection 9, though this contradicts the strong evidence-based recommendations from AABB and ASCO